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Abstract
Background: 17-Allylamino-17-demethoxygeldanamycin (17-AAG), a benzoquinone ansamycin antibiotic,
specifically targets heat shock protein 90 (Hsp90) and interferes with its function as a molecular chaperone that
maintains the structural and functional integrity of various protein clients involved in cellular signaling. In this
study, we have investigated the effect of 17-AAG on the regulation of Hsp90-dependent signaling pathways
directly implicated in cell cycle progression, survival and motility of human urinary bladder cancer cell lines.
Methods: We have used MTT-based assays, FACS analysis, Western blotting, semi-quantitative RT-PCR,
immunocytochemistry and scratch-wound assay in RT4, RT112 and T24 human urinary bladder cancer cell lines.
Results: We have demonstrated that, upon 17-AAG treatment, bladder cancer cells are arrested in the G1 phase of
the cell cycle and eventually undergo apoptotic cell death in a dose-dependent manner. Furthermore, 17-AAG
administration was shown to induce a pronounced downregulation of multiple Hsp90 protein clients and other
downstream effectors, such as IGF-IR, Akt, IKK-a, IKK-b, FOXO1, ERK1/2 and c-Met, resulting in sequestration-
mediated inactivation of NF-B, reduced cell proliferation and decline of cell motility.
Conclusions: In total, we have clearly evinced a dose-dependent and cell type-specific effect of 17-AAG on cell
cycle progression, survival and motility of human bladder cancer cells, due to downregulation of multiple Hsp90
clients and subsequent disruption of signaling integrity.
Background
Urinary bladder cancer is the fifth most common malig-
nancy in the industrialized world and the second most
frequent malignancy of the genitourinary tract, demon-
strating high heterogeneity and differential response to
clinical treatment [1,2]. Bladder cancer incidence, mor-
bidity and mortality rates vary by genetic background,
country, gender and age [3]. The most prevalent type of
bladder cancer in the developed world is urothelial
carcinoma (UC), representing over 90% of all bladder
cancers, followed by squamous cell carcinoma (5%) and
adenocarcinoma (2%) [4]. A high percentage of bladder
cancer patients (20-30%) present with an aggressive
muscle-invasive tumor of low differentiation, whereas
the rest develop superficial, highly differentiated, non-
invasive papillary tumors, 30% of which, nevertheless,
are estimated to recur to invasive. Unfortunately, more
than half of the patients with invasive tumors will
develop distant metastases over a time period of two
years [5], while the five-year survival rate for metastatic
d i s e a s ei sa sl o wa s6 % .T h i sa p p a r e n th e t e r o g e n e i t yi n
bladder cancer is thought to be mainly due to discrete
genetic alterations involved in tumor development and
progression. Thus, since established systemic che-
motherapy protocols for metastatic urothelial carcinoma
are associated with significant toxicities, new clinical
protocols designed for higher efficiency, while reducing
the adverse side effects, are urgently needed.
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emerged as an important target in cancer therapy.
Hsp90 normally accounts for approximately 1-2% of the
total cytosolic protein content, while under stress condi-
tions, its levels increase up to 4-6% of the whole proteo-
mic load of the cell [6-8]. The Hsp90 chaperone activity
relies on its transient NH2-terminal dimerization, which
facilitates its intrinsic ATPase activity [9]. The Hsp90
chaperone complex maintains the correct folding, cellu-
lar localization and activity of a broad range of protein
clients that are implicated in various signal transduction
pathways involved, among others, in cell proliferation,
differentiation and survival [7,10]. There is evidence that
Hsp90 is a major facilitator of cellular response to extra-
cellular signals, particularly required for normal cell
growth, proliferation and development [11]. On the
other hand, over-expression and/or presence of muta-
tions in a variety of Hsp90 protein clients during cancer
initiation is associated with a requirement for increased
Hsp90 levels in order to maintain the active conforma-
tions and thus functional integrities of these oncogenic
molecules. In this frame, Hsp90 is a key molecule in the
conformational maturation of several bona fide onco-
genic signaling proteins, such as HER2/ErbB2, Akt, Met,
Raf1, p53 and HIF-1a [10,12]. Therefore, due to the
dependence of cancer cells upon specific Hsp90 onco-
genic protein clients, inhibition of Hsp90 was shown to
be able to negatively interfere with a number of impor-
tant signaling pathways involved in cell development,
proliferation, survival and motility, arousing significant
interest in the field of cancer therapeutics [13].
Thus, a diverse group of molecules that target Hsp90
have been discovered or synthesized over the past
several years. These include natural products, such as
geldanamycin, radicicol and derivatives; synthetic pur-
ine-based inhibitors, such as PU3, PU24FCI and
PU29FCI; and compounds that bind to Hsp90 on a
secondary ATP-binding site, such as novobiocin and
cisplatin [6]. The geldanamycin derivative 17-allylamino-
17-demethoxygeldanamycin (17-AAG) possesses an ally-
l a m i n og r o u pa tp o s i t i o n1 7o ft h es c a f f o l ds t r u c t u r eo f
geldanamycin [6]. Compared to the parental compound,
17-AAG demonstrates reduced toxicity, with enhanced
biological activity and metabolic stability, retaining the
Hsp90-related therapeutic characteristics. 17-AAG
exerts its anti-tumor potency through its high affinity
binding to the NH2-terminal ATP-interacting domain of
Hsp90, thus inhibiting its ability to form transient, active
homodimers, and to consequently participate in chaper-
one-client complexes, with a subsequent hindering of
client maturation and stabilization.
In this context, here, we have thoroughly studied the
effects of Hsp90 inhibition by 17-AAG on the Hsp90-
assisted signaling repertoire associated with cell cycle
progression, apoptosis and motility in three human urin-
ary bladder cancer cell lines of different malignancy




17-AAG chemotherapeutic reagent was obtained from
InvivoGen (San Diego, California, USA). Polyclonal and
monoclonal antibodies against Caspase-8, Caspase-9,
Caspase-3, PARP, Lamin A/C, phospho-Akt (Ser473),
phospho-Akt (Thr308), Akt, phospho-IGF-ΙRb
(Tyr1131), IGF-ΙRa, FOXO, phospho-FOXO, phospho-
IKKa/b (Ser180/Ser181), IKKa,I K K b, phospho-p44/42
(Thr202/Tyr204), p44/42, a-tubulin, phospho-c-Met
(Tyr1234/Tyr1235), c-Met, CHIP and pan-actin were
purchased from Cell Signaling Technology Inc. (Hert-
fordshire, UK), whereas antibodies against Hsp90a/b,
Hsp70, Cdk4, pRb, E2F1 and NF-B (p65) were supplied
by Santa Cruz Biotechnology Inc. (California, USA).
Enhanced Chemilluminescence (ECL) Western blot
detection reagents were obtained from GE Healthcare
Life Sciences (Buckinghamshire, UK). Oligonucleotide
primers were synthesized by Operon (California, USA).
All other chemicals were of analytical grade from
Sigma-Aldrich (Missouri, USA), Fluka (Hannover, Ger-
many) and AppliChem GmbH (Darmstadt, Germany).
Cell lines and culture conditions
The present study was performed on three human urin-
ary bladder cancer cell lines, namely RT4, RT112 and
T24, all originating from urothelial carcinomas. RT4
cells are derived from grade I tumor and were obtained
from the European Collection of Animal Cell Cultures
(Salisbury, UK); RT112 cells are derived from a grade
I®II tumor, whereas T24 cells are derived from a grade
III tumor. RT112 and T24 cells were a generous gift
from Professor J. R. Masters (Prostate Cancer Research
Centre, Institute of Urology, University College London,
UK). Cells were maintained in DMEM, supplemented
with 10% heat inactivated FBS, at 37°C in a humidified
5% CO2 atmosphere. All cell culture media and reagents
were supplied by Biochrom AG (Berlin, Germany).
Cell viability assay
Urinary bladder cancer cells were seeded at a density of
15-20 × 10
3 per well into 48-well plates and treated
with various drug concentrations for 24 h. The next
day, cells were incubated in methylthiazole tetrazolium
(MTT) solution. The spectrophotometric absorbance
was measured in an ELISA microtiter plate reader
(Dynatech MR5000, Dynatech Laboratories, Virginia,
USA) at 550 nm, using measurement at 630 nm as
reference. Absorbance rates obtained by untreated cells
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repeated at least three times, using three wells per drug
concentration in each experimental condition.
Cell cycle analysis
Bladder cancer cells were seeded at a density of approxi-
mately 5 × 10
5 in 100 mm plates and drug treatments of
different concentrations of 17-AAG were applied for 24
h. Cells were collected, fixed in 1% methanol-free for-
maldehyde for 20 min and subsequently suspended in a
70% ethanol solution and stored at -20°C to dehydrate.
Twenty four hours later, cells were suspended in 1 ml
of 0.1% Triton X-100 solution and incubated in 500 μl
of propidium iodide solution (50 μg/ml) containing 250
μg of DNase-free RNase A. Cells were analyzed with a
Beckton Dickinson’s FACScalibur (California, USA) at
542 nm and results were processed with the Modfit
software program. Each assay was repeated three times.
Immunoblotting
Whole cell protein extracts were prepared as previously
described [14]. Approximately 30 μg of total protein
preparations were resolved by SDS-polyacrylamide gel
electrophoresis and subsequently electro-transferred
overnight onto nitrocellulose membranes of 0.45 μm
pore size (Schleicher and Schuell GmbH, Dassel, Ger-
many). Membrane blocking was performed in TBS-T
(20 mM Tris-HCl, pH 7.6, 137 mM NaCl and 0.1%
Tween-20) containing 5% non-fat dry milk (or 5% BSA
grade V, where appropriate) and membranes were incu-
bated with the appropriate antibodies at room tempera-
ture for 90 min, followed by an overnight incubation at
4°C. The next day, membranes were incubated with the
suitable anti-mouse or anti- r a b b i tH R P - c o n j u g a t e ds e c -
ondary antibody and immunoreacting proteins were
detected using an ECL Western blotting kit according
to the manufacturer’s instructions. All immunoblotting
experiments were repeated three times.
RT-PCR analysis
Total RNA from both control and treated cells was
extracted as previously described [14]. 1 μl of cDNA solu-
tion was amplified by PCR in a total volume of 25 μl,
using cDNA-specific primers corresponding to the various
mRNA species examined in the present study. Most gene-
specific cDNA primer sequences and associated PCR
information have been previously described [14,15],
whereas additional genes amplified for the purpose of this
study were: Cyclin D1 (forward: 5′-GTGTCCTACTT-
CAAATGTGTGC-3′, reverse: 5′-GGAGTTGTCGGTG-
TAGATGC-3′, Ta: 57°C, 30 cycles), Hsp90a (forward: 5′-
CCAAGATGCCTGAGGAAAC-3′,r e v e r s e :5 ′-TCA-
TACCGGATTTTGTCCAAT-3′ Ta: 53°C, 30 cycles) and
Hsp90b (forward: 5′-TCCTTTTCTTTTCAAGATGCC-3′,
reverse: 5′-TGTCCAACTTCGAAGGGTCT-3′, Ta: 54°C,
30 cycles). The obtained PCR fragments were resolved in
2% agarose gels, according to standard procedures. All
RT-PCR experiments were repeated three times.
Immunofluorescence
T24 urinary bladder cancer cells were seeded on poly-L-
lysine coated slides (Thermo Fisher Scientific Inc., Min-
nesota, USA) and treated with a 17-AAG concentration
of 10 μM for 24 h. After treatment, slides were fixed
with a paraformaldehyde solution (3% in 1 × PBS) for
15 min at room temperature. Cell permeabilization was
achieved by administration of a Triton X-100 solution
(0.5% in 1 × PBS) for 20 min. Subsequently, slides were
blocked with a 1% BSA solution for 60 min and then
incubated with an NF-B anti-p65 antibody overnight at
4°C. The next day, slides were incubated with a FITC-
conjugated anti-rabbit secondary antibody (Jackson
ImmunoResearch Laboratories Inc., Pennsylvania, USA),
while nuclear staining of cells was obtained by incuba-
tion with propidium iodide solution (1 μg/ml in 1 ×
PBS containing RNase A). Finally, cells were observed
under a Nikon EZ-C1 confocal microscope (Nikon
Instruments Inc., Japan). Images taken were processed
with the support of the Nikon EZ-C1 software program.
Immunofluorescence experiments were repeated three
times.
Scratch-wound assay
Human urinary bladder cancer cells were seeded at a
density of 5 × 10
5 per 100 mm diameter Petri dish and
incubated overnight. The day after, the surfaces of the
dishes were mildly scratched with a sterile Pasteur pip-
ette and images were taken under a Carl Zeiss Axiovert
25 (Thornwood New York, USA) inverted microscope
with the use of a Cannon Powershot G9 digital camera
and a PS-Remote software program. Then, cells were
treated with a 10 μΜ 17-AAG solution and incubated
overnight at 37°C in a humidified 5% CO2 atmosphere.
Twenty four hours later, treated and untreated cells
were observed under the inverted microscope at the
scratch-wounded areas. Scratch-wound assays were
repeated three times.
Results
17-AAG displays an inhibitory effect on cell cycle pro-
gression of human urinary bladder cancer cells. We have
studied the effect of 24-hours 17-AAG treatment on the
course of the cell cycle of RT4, RT112 and T24 human
urinary bladder cancer cells using flow cytometry
(Figure 1). As presented herein, RT4 cancer cells dis-
played a G1 arrest (from 54.5% in the control to 69.4%
at 10 μM), while a G2-phase inhibition was also
observed (from 14% in the control to 30.6% at 10 μM),
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ment with 17-AAG, RT112 presented an increase in the
percentage of cells accumulating in G1 phase (from
64.4% in the control reaching a peak value of 77.3% at
the 1 μΜ dosage), accompanied by a possible S block,
since the percentage of cells in the S phase remained
practically unchanged (from 26% to 27.5%), whereas the
number of cells in phase G2 was constantly decreasing
(from 9.6% to 0%). Treatment of T24 cells with 17-AAG
was able to induce a moderate G1 block (from 75.8% in
the control to 81.3% at 10 μΜ), while it was also found
to cause an additional mild arrest of the cell cycle
in phase G2 (from 12.4% in the control to 17.9% at
10 μΜ).
In order to further illuminate the G1 block observed,
we examined the effect of 17-AAG on Cyclin/Cyclin-
dependent kinase (Cdk) complex components, which
assist dividing cells to overcome the G1-phase check-
point (Figure 2A). We have found that Cdk4 protein
levels display a dose-dependent and cell type-specific
decrease, with Cdk4 downregulation being more promi-
nent in RT112 than RT4 cells, whereas in T24 this was
kept to a minimum. A similar pattern of downregulation
in all the cell lines was demonstrated when studying the
expression levels of Cyclin D1 mRNA, with T24 exposed
to the higher drug dose manifesting the most severe
response, hence suggesting a possible Cyclin D1 and
Cdk4 involvement in the observed 17-AAG-induced G1
cell cycle block (Figure 2A). Furthermore, the expression
and activation of other downstream significant modula-
tors of cell cycle progression, such as pRb protein and
its interacting partner transcription factor E2F1 were
examined (Figure 2B). After treatment with 17-AAG,
pRb protein levels were shown to display a dose-depen-
dent downregulation in all three cell lines examined in
this study. Interestingly, in RT4 cells pRb protein is not
phosphorylated either in the control or after drug expo-
sure, whereas phosphorylation in RT112 and T24 was
found to decrease with increasing 17-AAG doses, in a
cell type-specific manner. In relation to this, E2F1 pro-
tein levels also displayed a clear downregulation pattern
in all three cell lines, rendering this transcription factor
practically undetectable in the higher doses (1 and 10
μM), also suggesting a possible E2F1 involvement in the
observed 17-AAG-induced G1 cell cycle block.
17-AAG manifests a cytotoxic effect on human bladder
cancer cell lines. To assess the biological effect of 17-
AAG on bladder cancer cell survival, we performed
MTT assays on RT4, RT112 and T24 cells, incubated
with increasing concentrations of the drug for 24 and
48 hours (Figures 3 and 4). All three cell lines showed a
dose-dependent decrease in cell viability. It seems that
RT112 cells are more sensitive than RT4 to the cyto-
toxic activity of 17-AAG after 24 hours of treatment,
Figure 1 Cell cycle progression analysis of human bladder cancer cells treated with 17-AAG for 24 hours. Representative FACS analysis
of RT4, RT112 and T24 bladder cancer cells and percentage of total cell content in distinct phases of the mitotic course are displayed. The cell
cycle experiments were repeated three times.
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bers of cells, alive but committed to apoptosis at 24
hours, were dead after 48-hours treatment, so the per-
centage in cell survival was dramatically decreased and
almost equal in all three bladder cancer cell lines.
17-AAG induces activation of Caspase-dependent
death processes in bladder cancer cells. 17-AAG-induced
reduction of cell survival was found to be associated
with proteolytic cleavage of critical members of the Cas-
pase family (Caspase-8, Caspase-9 and Caspase-3) and
characteristics of apoptotic death. Protein expression
levels and activation of Caspase proteases are shown in
Figure 5. The downregulation patterns of precursor Cas-
pase protein levels were more pronounced in RT112
cells, combined with dose-dependent increases in pro-
teolytic cleavage products of Caspase-8 (43, 41 and 18
kDa), Caspase-9 (37 and 35 kDa) and Caspase-3 (19 and
17 kDa). These data clearly demonstrate the ability of
17-AAG to induce Caspase-dependent death in all three
bladder cancer cell lines studied here. This fact was
Figure 2 17-AAG-induced G1 cell cycle block is due to downregulation of specific Hsp90 clients. (A) Detection of Cdk4 protein (Western
blotting) and Cyclin D1 gene (RT-PCR), both critically implicated in the G1 to S phase transition, over a 24-hours treatment period of human
bladder cancer cells with 17-AAG. The mRNA expression levels of the internal control gene GAPDH were also quantified by an RT-PCR approach.
(B) Western blotting of the cell cycle regulatory proteins pRb and E2F1, after exposure of RT4, RT112 and T24 cells to different 17-AAG doses.
Immunoblotting and RT-PCR experiments were repeated three times.
Figure 3 MTT cytotoxicity assays performed on RT4, RT112 and
T24 bladder cancer cells, upon 24 hours of treatment with 17-
AAG. All assays were implemented three times, while the obtained
standard deviations (error bars) are depicted on the top of each
value bar.
Figure 4 MTT cytotoxicity assays performed on RT4, RT112 and
T24 bladder cancer cells, upon 48 hours of treatment with 17-
AAG. All assays were implemented three times, while the obtained
standard deviations (error bars) are depicted on the top of each
value bar.
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the Caspase repertoire substrates PARP and Lamin A/C
upon administration of relatively high concentrations of
17-AAG (1 and 10 μΜ) in RT4, RT112 and T24 bladder
cancer cell lines.
Exposure of human bladder cancer cells to 17-AAG
results in downregulation of Hsp90. The effect of 17-AAG
administration on Hsp90 and co-chaperone Hsp70 struc-
tural integrities in RT4, RT112 and T24 bladder cancer
cells was examined by western immunoblotting (Figure
6A). In RT4 cells, 24 h incubation with 17-AAG resulted
in a dose-dependent reduction of Hsp90 protein levels,
up to the concentration of 1 μΜ. Intriguingly, at the
highest dose of 10 μΜ, the levels of Hsp90 protein rose
again significantly, disrupting the downregulation pat-
tern, whereas an Hsp90 cleavage product with a molecu-
lar weight of approximately 65 kDa was generated. The
same pattern of initial reduction (lower doses) and fol-
lowing increase (higher doses) of total Hsp90 protein
levels was observed in RT112 cells as well, only this was
found to occur at even lower doses. More specifically,
RT112 cells displayed maximum Hsp90 downregulation
at the dose of 0.1 μM 17-AAG, whereas a significant
Figure 5 17-AAG activates Caspase-dependent death processes
in bladder cancer cells. Apoptotic death induced by 17-AAG
administration in human urinary bladder cancer cells was
characterized by reduced expression and proteolytic cleavage
profiles of apoptosis-related proteins, in response to various drug
concentrations, for 24-hours exposure period. Treatment of RT4,
RT112 and T24 cells with 17-AAG resulted in prominent cleavage
and activation of critical members of the Caspase apoptotic
machinery in all three cell lines, along with notable proteolytic
processing of the Caspase repertoire characteristic substrates PARP
and Lamin A/C. All apoptosis immunoblotting experiments were
repeated three times.
Figure 6 17-AAG-induced downregulation of Hsp90 in urinary bladder cancer cells, after 24 hours of drug treatment.( Α)T o t a la n d
truncated protein levels of critical members of the “chaperosome”, such as Hsp90, Hsp70 and CHIP, are visualized by a Western blotting
approach. Pan-actin was used as protein of reference, while a-tubulin revealed a similar to Hsp90 expression profile. The transcriptional activity
analysis of Hsp90 genes (a and b), in response to 17-AAG, is provided in (B). All experiments were repeated three times.
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at 1 and 10 μM of 17-AAG, with production of the
H s p 9 0c l e a v a g ef r a g m e n ta tt h eh i g h e s td r u gd o s e( 1 0
μM). This pattern could not be detected in the malignant
cell line T24, where the levels of Hsp90 proved to follow
a consistent dose-dependent decrease. Regarding the pro-
tein levels of Hsp70 co-chaperone, these appear to follow
a dose-dependent increase, which becomes quite signifi-
cant in response to relatively high doses of 17-AAG (1
and 10 μΜ) in all three cell lines. In addition, at the two
(RT4) or three (RT112 and T24) higher doses of the drug
(0.1, 1 and 10 μM ) ,w ew e r ea b l et od e t e c tt h ep r e s e n c e
of an Hsp70 protein cleavage product with a molecular
weight of approximately 65 kDa, which also seemed to
display a cell type-specific and dose-dependent formation
pattern.
In order to study the cause of the 17-AAG-induced
response pattern of Hsp90 in the three cell lines, we
decided to analyze the expression of another member of
the Hsp90 chaperone complex, namely Carboxyl termi-
nus of Hsp70 interacting protein (CHIP), an E3 ubiqui-
tin ligase, which regulates the turnover of Hsp90 protein
clients in mammalian cells, but also Hsp90 itself, via
ubiquitination of specific residues of the chaperone,
therefore making it a suitable candidate for proteasomal
degradation [16-18]. In the bladder cancer cell lines
used in this study, CHIP showed a dose-dependent and
cell type-specific decrease in response to 17-AAG
administration, with RT4 and RT112 cells exhibiting the
most notable reduction, whereas CHIP protein control
levels were found to steadily increase from RT4 to
R T 1 1 2a n dt h e nT 2 4c e l l s .P a n - a c t i nw a su s e da sp r o -
tein of reference in all experiments performed herein,
whereas a-tubulin, interestingly, appeared to follow an
expression pattern very similar to that of Hsp90. This is
consistent with the recently discovered association
between tubulin and the Hsp90 chaperone complex [19].
Finally, we examined the transcriptional profiles of
Hsp90a and Hsp90b genes in response to the drug, in
order to identify a possible association of 17-AAG-
induced Hsp90 downregulation with transcriptional
repression of Hsp90 genes. In this frame, Hsp90 mRNA
expression levels were tested and found to remain unaf-
fected in all the cell lines used here (Figure 6B), thus
excluding any type of transcriptional control involve-
ment in the 17-AAG-induced downregulation of Hsp90
protein.
17-AAG administration leads to downregulation of cri-
tical targets in the IGF-IR/Akt signaling pathway and
results in NF-Bi n a c t i v a t i o n .U p o ne x p o s u r et o1 7 -
AAG, a variety of Hsp90 protein clients, mainly kinases
and transcription factors, were shown to be notably
downregulated in the human urinary bladder cancer cell
lines used in this study (Figure 7). In response to the
Figure 7 17-AAG administration results in functional attenuation of Akt signaling in bladder cancer cells. Inhibition of Hsp90 leads to
prominent downregulation of the Akt-dependent signaling pathway, presenting with pronounced decrease of constitutively phosphorylated,
and therefore activated, IGF-I receptor, Akt kinase and downstream signaling components, such as members of the IKK family (IKKa and IKKb). All
experiments were repeated three times.
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showed a prominent dose-dependent reduction in all
three bladder cancer cell lines, with T24 exhibiting the
most potent effect (Figure 7). Remarkably, even though
in RT112 and T24 cells the phosphorylated receptor
levels, albeit weak in the former and strong in the latter,
were similarly found to decrease in a dose-dependent
manner, in RT4 cells no phosphorylation of the IGF-IR
protein could ever be detected.
A prominent downstream target of the IGF-I receptor
and distinguished protein member of the Hsp90 clien-
tele is the Akt kinase, a critical regulatory component in
many signaling pathways. Upon administration of 17-
AAG, Akt proved to be downregulated in all three blad-
der cancer cell lines, in a dose-dependent manner
(Figure 7). Interestingly, in RT112 cells we were able to
observe the formation of a lower molecular weight frag-
ment, possibly representing a cleavage product of the
intact Akt kinase (55 kDa, approximately), specifically
generated after exposure to 1 and 10 μM 17-AAG.
Next, we tested the presence of phosphorylated Akt in
the same cells before and after 17-AAG treatment. Even
though phosphorylation of Akt on serine residue at
position 473 (Ser473) could not be detected in RT4, it
was marginal in RT112, and highly activated in T24
cells. In RT112 and T24 cell lines, Akt phosphorylation
showed a dose-dependent decrease, resulting in an
almost total elimination of the active form of the protein
from drug concentrations higher than 0.1 μM for RT112
and 1 μM for T24 cells. Akt phosphorylation on threo-
nine residue at position 308 (Thr308) ranged from
absent (RT4 and T24) to marginal (RT112) levels.
17-AAG-induced Akt functional repression and degra-
dation was accompanied by expression level reduction
of the downstream targets ΙΚΚa and IKKb,w h i c h
clearly exhibit a dose-dependent downregulation pattern
consistent with their status as bona fide Hsp90 chaper-
one clients. Moreover, the activated forms of IKKa and
IKKb kinases, phosphorylated on serine residues at posi-
tions 180 and 181, respectively, were detected at very
low levels in all three cell lines (with T24 revealing the
strongest expression profile), exhibiting a dose-depen-
dent inhibition in response to 17-AAG administration.
Furthermore, the combinational inhibitory effect of 17-
AAG on key molecules of the IGF-IR/Akt/IKK axis was
found to induce inactivation of NF-B transcription fac-
tor, a downstream target of this pathway, ultimately
resulting in its relocation to the cytoplasm, therefore
rendering it unable to exert regulatory control upon a
vast number of genes involved in cell proliferation and
survival. As illustrated in Figure 8A, it is clear that 17-
AAG promotes NF-B inactivation in T24 bladder can-
cer cells due to nuclear exclusion of the factor, in con-
trast to the compartmentalization profile observed in
control cells, where NF-B is located both inside the
nucleus and the cytoplasm. To reinforce our findings on
17-AAG-induced NF-B inhibition in bladder cancer
cells, the mRNA expression of two representative anti-
apoptotic NF-B target genes, namely cIAP1 and Survi-
vin, was examined using an RT-PCR approach
(Figure 8B). Thus, in response to 17-AAG, both genes
were found to be downregulated in a cell type-specific
and dose-dependent manner, with RT4 and RT112 cells
displaying stronger reductions of mRNA levels com-
pared to the malignant T24 ones.
In addition, we examined one critical group of Akt
downstream targets tightly associated with cell death
inhibition signaling, the Forkhead family of transcription
factors (FOXO: Forkhead box O). As shown in Figure 9,
total FOXO1 protein detected at 78 kDa was found to
display a characteristic cell type-specific and dose-
dependent reduction in response to the drug, which was
incomparably prominent in RT112 cells. On the other
hand, total FOXO4 protein levels in all three bladder
cancer cell lines exhibited an expression pattern similar
to the one observed for Hsp90 and a-tubulin (Figure 9,
the lowest band of 68 kDa). Furthermore, the phosphor-
ylation status of FOXO proteins was also examined. In
RT4 cells, no detectable phosphorylated FOXO tran-
scription factors could be observed, while in RT112 cells
only phospho-FOXO3 was traced in the control with
subsequent elimination starting from the lowest drug
dose. Interestingly, T24 cells were characterized by high
levels of phosphorylated FOXO1 and FOXO3 proteins,
likely reflecting the low differentiation level of these
cells, whereas exposure to 17-AAG resulted in dose-
dependent downregulation of both phosphorylated
FOXO family members, supporting the induction of
dephosphorylation-mediated nuclear sequestration
of the Forkhead factors, with subsequent transactivation
of apoptotic target genes.
Furthermore, we studied the effect of 17-AAG on the
Ras-Raf-MEK-ERK pathway (known to usually cross-talk
with Akt) in bladder cancer cells, by detection of total
and phosphorylated p44/42 (Erk1/2) kinase protein
levels. As illustrated in Figure 9, upon 17-AAG adminis-
tration, total p44/42 levels in both RT4 and RT112 cell
lines exhibited a pattern reminiscent of the one pre-
viously encountered in Hsp90, a-tubulin and FOXO4.
More precisely, in RT4 cells, p44/42 protein levels dis-
played a pattern of dose-dependent downregulation up
to 1 μM concentration of the drug, whereas a significant
increase could be observed in the highest dose (10 μM).
In RT112 cells, the pattern was similar, but shifted to
lower concentrations. Thus, total p44/42 protein levels
were found to manifest a drug-mediated reduction in
the lower concentrations only, whereas in the higher
ones a clear increase could be observed. On the
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dent decrease of p44/42 expression levels was observed.
In order to evaluate the potency of p44/42 signal trans-
duction upon exposure to 17-AAG, the active form of
the protein (phosphorylated on threonine and tyrosine
residues at positions 202 and 204, respectively) was ana-
lyzed. As shown in Figure 9, all three cell lines
demonstrated a severe dose-dependent reduction of
active p44/42, therefore causing the downregulation of a
variety of downstream targets, mainly involved in cell
proliferation and survival. In toto, 17-AAG proved to
induce a prominent inhibitory effect upon multiple
Hsp90 clients, affecting both the NF-Ba n dt h eF O X O
axes of the IGF-IR/Akt signaling repertoire, as well as
Figure 8 NF-B functional impairment, in response to 17-AAG administration in bladder cancer cells. (A) Characteristic
immunofluorescence images of T24 cells presenting NF-B (green color) cellular localization, under control (i-iii) or 10 μM of 17-AAG (iv-vi)
treatment conditions (scale bars: 10 μm). Nuclear counterstaining was performed by the utilization of propidium iodide, while images were
visualized by Confocal microscopy and appropriately merged to reveal NF-B localization in bladder cancer cells (white arrows). (B) Expression
profiles of the two anti-apoptotic NF-B target genes cIAP1 and Survivin in RT4, RT112 and T24 bladder cancer cells, upon exposure to 17-AAG
for 24 hours. All experiments were repeated three times.
Figure 9 17-AAG induces downregulation of FOXO and ERK1/2 signaling mediators in bladder cancer cells. Detection of total and
constitutively phosphorylated protein levels of FOXO transcription factors and Erk1/2 (p44/42) kinases in all three bladder cancer cell lines, upon
17-AAG administration for 24 hours, via a Western blotting approach. All immunoblotting experiments were repeated three times.
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downregulation of downstream targets and finally lead-
ing to decreased cell proliferation and survival.
17-AAG administration reduces urinary bladder can-
cer cell motility. Cancer cell motility is an important
determinant of epithelial-mesenchymal transition
(EMT), which underlies the early phase of the tumor
invasion program. One of the key components in EMT-
dependent tumor proliferation, cell motility and invasion
signaling is the hepatocyte growth factor (HGF) recep-
tor, also referred to as c-Met. In order to assess the
effect of 17-AAG on c-Met pathway activation in RT4,
RT112 and T24 bladder cancer cell lines, we have exam-
ined the total and phosphorylated protein levels of
c-Met in response to drug exposure. As shown in Figure
10A, the low malignancy grade RT4 and RT112 cells
were characterized by non to slightly detectable total c-
Met protein levels, respectively, whereas in grade III
T24 cells, c-Met protein could be easily recognized,
exhibiting a drug dose-dependent downregulation pat-
tern and reaching a complete elimination by the 1 μM
dose of 17-AAG. The phosphorylated, active form of the
protein was observed exclusively in high grade T24 cells,
displaying a dose-dependent reduction profile, whereas
RT4 and RT112 cells presented with undetectable
(or hardly detectable) levels of constitutive activation
(Figure 10A).
To further illuminate the effect of 17-AAG on the effi-
ciency of bladder cancer cell motility, we have con-
ducted scratch-wound assays on all the cell lines
examined herein (Figure 10B). As clearly demonstrated
in this work, the low malignancy grade cell lines RT4
and RT112 presented with reduced proliferation and
motility potency, unable to heal the “wounds” during a
24-hours incubation period, either under high 17-AAG
concentration (10 μΜ) or control conditions (Figure
10B, RT4: panels i-iv, RT112: panels v-viii). In contrast,
the highly aggressive (grade III) T24 cells were charac-
terized by a prominent efficiency in motility, being able
to successfully “heal the wound” in an incubation period
of 24 hours, creating a compact monolayer of cells (Fig-
ure 10B, panels ix and x). Although administration of 10
μΜ 17-AAG was not able to abrogate T24 proliferation
and motility responses, it is clear that the scratch-
wound “healing” mechanism in these cells has been sig-
nificantly impaired due to the effect of the drug, since
Figure 10 Exposure to 17-AAG results in reduced cancer cell motility and proliferation. (A) Western blotting analysis revealing the
expression profile of total and phosphorylated c-Met protein in all three bladder cancer cell lines, upon a 24-hours incubation with different
concentrations of 17-AAG. (B) Scratch-wound assays conducted on RT4 (i-iv), RT112 (v-viii) and T24 (ix-xii) cells, under control conditions or in the
presence of 10 μM 17-AAG. T24 highly malignant cells display strong wound-healing potential (panel xi) over a 24-hours period, compared to
RT4 and RT112 (panels iii and vii, respectively) cells, under control conditions. Interestingly, 17-AAG administration induces a moderate
impairment of T24 cell motility and proliferative dynamics (panel xii), thus only partly prohibiting, in contrast to RT4 and RT112, the efficient
closure of the gap (scratch-wound). Cells were observed under an inverted microscope and pictures were taken at a 20 × magnification. All
experiments were repeated three times.
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condensed as initially observed under control conditions
(Figure 10B, panels xi and xii).
Discussion
Human urinary bladder cancer is considered an increas-
ingly significant public health issue in the industrialized
countries, with a worldwide estimate of about two mil-
lion patients [2]. Due to the importance of Hsp90 mole-
cular chaperone on client protein maturation and
function, along with its voluminous and highly diverse
clientele of cancer-related proteins, a variety of Hsp90
inhibitors have emerged as promising anticancer agents
[6,12]. In the present study, we have comparatively
examined the effects of 17-AAG-induced Hsp90 inhibi-
tion on multiple protein targets implicated in signaling
pathways critically regulating cell proliferation, apoptosis
and motility, in RT4 (grade I), RT112 (grade I-II) and
T24 (grade III) human urothelial bladder cancer cells.
The data presented herein clearly demonstrate that,
upon 17-AAG treatment, cell type-specific downregula-
tion of multiple signaling molecules is followed by cell
cycle arrest, finally resulting in Caspase-mediated cell
death.
Depending on the cellular context and malignancy
grade, 17-AAG has been shown to facilitate arrest in all
checkpoints of the cell cycle, as for example, in human
malignant pleural mesothelioma (G1 or G2/M block)
[20] and breast cancer cells (G1 block) overexpressing
HER2 [21]. In all human bladder cancer cell lines exam-
ined in this study, apoptotic cell death was found to be
preceded predominantly by a drug dose-dependent G1/S
cell cycle block, with arrest in other phases of the cell
cycle appearing in a cell type-specific manner. The
unpredictability of cell cycle arrest induced by 17-AAG
in bladder cancer cells is in agreement with previous
reports and might be related to differences in client pro-
tein repertoires and cellular contexts [22]. To elucidate
the 17-AAG-induced block of the cell cycle, we under-
took analysis of expression and/or activation profiles of
several key-modulators of cell cycle progression. This
demonstrated that, in response to 17-AAG exposure,
the drug-dependent protein downregulation patterns
correlate well with the observed G1 arrest of the cell
cycle, as well as with the reduction in cell proliferation
capacity.
Implementation of apoptosis, due to the effect of 17-
AAG, has previously been reported in glioblastoma [23]
and colon cancer [24]. In the bladder cancer cell lines
used in this study, cell type-specific and drug dose-
dependent activation of a Caspase-induced cell death
program proved to be initiated upon 17-AAG adminis-
tration. These findings are in accordance with the survi-
val rates observed in the cytotoxicity tests, although, in
these experiments, 17-AAG-induced cell death percen-
tages in the three bladder cancer cell lines were not
found to differ significantly. In contrast, the cell-type
specific profile of Caspase repertoire activation, and
especially the diminished levels of processed Caspase-3
in RT112 and T24 cells, could possibly implicate other
types of executive Caspases not studied here (i.e. Cas-
pase-6 or -7) or even Caspase-independent cell death
mechanisms such as autophagy [25,26].
Hsp90 expression levels seem to be upregulated in
cancer, resulting in addiction of tumor cells to multiple
oncogenic pathways in which Hsp90 clients play a criti-
cal role. In bladder cancer, Hsp90 was found to be
e x p r e s s e di nm o r et h a n9 0 %o fh u m a nt u m o rs p e c i -
mens, with high-grade and muscle invasive tumors
expressing significantly higher levels of Hsp90 than low-
grade and superficial tumours [27]. Nevertheless, in 10%
of the tumor samples Hsp90 expression was found to be
downregulated and this was associated with infiltrating
recurrences and poor prognosis [28,29], most likely due
to the overall molecular profile of the individual tumors.
Besides the importance of Hsp90 expression levels, spe-
cific conformations of the chaperone have been impli-
cated in cancer versus normal cell sensitivity to Hsp90
inhibitors: Hsp90 was shown to display higher binding
affinity for 17-AAG exclusively in cancer cells [30], lead-
ing to the formation of 17-AAG-sensitive Hsp90-con-
taining “superchaperone” complexes in malignant cells,
whereas normal cells bearing a predominantly uncom-
plexed Hsp90 are significantly less sensitive to these
types of inhibitors [13,30]. This feature is likely
exploited by Hsp90 targeting with the use of 17-AAG
and subsequent effects on multiple Hsp90 targets.
Hsp90 inhibition and subsequent Hsp70 and Hsp27
upregulation, due to 17-AAG, have been reported in
human colon [31], prostate [32] and cervical cancer cells
[32]. As presented in this study, even though a 17-AAG-
induced Hsp90 downregulation was detected in all blad-
der cancer cell lines over a 24-hours treatment period, a
cell type-specific pattern of inhibition was observed. In
RT4 and RT112 cells, after exposure to the highest dose
of the drug, an additional protein band was generated,
whereas no such band could be detected in T24 cells.
This novel finding in relation to Hsp90 structural integ-
rity, upon high dose of 17-AAG administration, is pre-
sented herein for the first time. We suggest that this
fragment may well be a product of Hsp90 proteolytic
processing by Granzyme B [14,15]. Use of the GrabCas
algorithm has revealed a putative Granzyme B recogni-
tion and cleavage site in the amino acid sequence of
both Hsp90a and Hsp90b protein isoforms, indicating
that Hsp90 must be a bona fide substrate of Granzyme
B. On the contrary, no Caspase cleavage site could be
identified, with the help of GrabCas, fitting to the
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ment under discussion. Interestingly, Hsp90 cleavage
has been reported previously, as a response to oxidative
stress factors [33], arsenic-based compounds [34] and
exposure to doxorubicin and cisplatin chemotherapeutic
agents [14,15]. Yet, it is not known whether the putative
cleavage product is associated, somehow, with malig-
nancy grade or p53 genetic status of the cells, since RT4
and RT112 are grade I and I-II, respectively, harboring a
wild-type p53, whereas T24 are grade III, bearing a
mutant p53 (Figure 6A). Intriguingly, the RT4- and
RT112-specific production of a ~ 65 kDa putative pro-
teolytic fragment could further enhance the functional
amputation effect of 17-AAG on Hsp90, likely acting as
a putative dominant negative component able to
severely impair Hsp90 chaperoning properties. Thus,
despite the Hsp90 upregulation observed in response to
the highest 17-AAG concentration in grade I (RT4) and
I-II (RT112) cell lines, the protein, due to its functional
titration by the ~ 65 kDa processed product, seems
unable to support its numerous clients thoroughly ana-
lyzed here. Therefore, we suggest that the chaperosomes
containing these Hsp90 truncated forms are most likely
inefficient to exert their cellular tasks.
The three bladder cancer cell lines seemed to follow a
distinct and cell type-dependent downregulation profile
of the Hsp90 molecular chaperone. However, as shown
herein, despite 17-AAG administration, gene expression
at the level of transcription remained unaffected for
both isoforms of Hsp90 (a and b), clearly indicating
that the regulation of Hsp90 is beyond transcriptional
control, but occurs more likely at the post-translational
level, via ubiquitination and subsequent proteasomal
degradation or autophagy.
Hsp90 inhibition was suggested to be tightly asso-
ciated with a compensatory upregulation of Hsp70 [31]
and/or Hsp27 protein levels, likely inducing resistance
to 17-AAG [32]. In this work, upon exposure to 17-
AAG, total Hsp70 expression levels proved to exhibit a
dose-dependent increase and generation of an ~ 65 kDa
protein fragment in all three cell lines, reaching peak
value at dose 10 μΜ. Using the GrabCas software, we
propose that, similarly to Hsp90, the lower molecular
weight band could likely represent a product derived
from Hsp70 proteolytic processing by 17-AAG-induced
Granzyme B activity, but not Caspase protease function.
CHIP was studied in order to illuminate the intriguing
pattern of Hsp90 protein level alterations after 17-AAG
treatment. CHIP levels were found to be downregulated
in a dose-dependent manner in all three bladder cancer
cell lines, suggesting a CHIP-regulated effect on protea-
somal degradation of associated target proteins, such as
Hsp90 and its clients. However, the higher dose-depen-
dent upregulation of Hsp90 and a-tubulin implies a
likely redundant, or non-essential, role of CHIP and,
therefore, other ubiquitin ligases must be critically
implicated in this type of response. An alternative sce-
nario is that affinity threshold phenomena are at play
here, with CHIP, although downregulated, still being
able to implement its ubiquitin ligase activities regarding
Hsp90 clients, but not Hsp90 itself.
The critical role of IGF-IR/Akt signaling pathway
deregulation in tumor cell proliferation, survival and
migration has been well documented [35]. It has been
previously reported that 17-AAG administration causes
severe inhibition of the Akt-dependent signaling path-
ways in osteosarcoma [36] and gastric cancer [37]. As
demonstrated here, in human urinary bladder cancer
cells, 17-AAG-induced inhibition of Hsp90 resulted in a
cell type-specific downregulation of several proteins
involved in Akt-dependent signaling, critically contribut-
ing to the negative regulation of proliferation, survival
and motility. As a consequence, NF-Bt r a n s c r i p t i o n
null activation potential was significantly compromised,
mainly due to the sequestration of the factor into the
cytoplasm, as clearly illustrated in Figure 8A. Reduced
NF-B activity was indirectly assessed by measuring the
mRNA expression levels of Survivin and cIAP1, two well
known bona fide NF-B target genes. Thus, we have
demonstrated that 17-AAG-dependent inhibition of NF-
B activity is tightly associated with transcriptional
repression of Survivin and cIAP1 anti-apoptotic genes,
thus decisively contributing to the cytotoxic potency of
17-AAG by decreasing the required “apoptotic thresh-
old” in bladder cancer cells [38].
Moreover, 17-AAG-mediated Hsp90 inhibition
resulted in alterations of the phosphorylation status of
members of the Forkhead family of transcription factors
(FOXO), immediate downstream substrates of Akt
kinase, in bladder cancer cells. As shown in this study,
FOXO factors proved to be strongly phosphorylated in
the highly malignant T24 cells, whereas extremely low,
but detectable, levels were also observed in RT112 cells.
Administration of 17-AAG caused a notable downregu-
lation of phosphorylated FOXO1 and FOXO3 family
members, likely inducing an enhancement of their apop-
totic activity.
Interestingly, the undetectable phosphorylation of the
IGF-I-dependent downstream mediators (i.e. IGF-IR,
Akt, IKKs and FOXOs) in RT4 cells strongly suggests
the deactivated character of the pathway under the par-
ticular growth conditions, whereas, on the contrary, in
T24 cells the IGF-IR/Akt pathway seems to be constitu-
tively activated. RT112 cells proved to display an inter-
mediate pattern of signaling potency, with the IGF-IR/
Akt pathway being activated at very low levels. This
novel finding of cell type-specific activation of the IGF-
IR/Akt-dependent signaling repertoire, herein
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ciated with the underlying differences in various features
of the malignant phenotype observed in the three blad-
der cancer cell lines examined.
Hsp90 inhibition and ensuing Akt inactivation in blad-
der cancer cells was accompanied by downregulation of
Erk1/2-dependent signaling. Exposure to 17-AAG has
been previously reported to cause inhibition of the Raf/
MEK/ERK signaling cascade in Hodgkin’sl y m p h o m a
[39] and leukemia [40]. Although total Erk1/2 protein
levels exhibited a cell type-specific and drug dose-
dependent response similar to the one of a-tubulin and
Hsp90, phosphorylated p44/42 levels were severely
downregulated in all bladder cancer cell lines, implying
the differential control between total and phosphory-
lated protein destabilization processes in response to the
high drug dose treatments.
Invasion and metastasis are one of the hallmark
traits of cancer involved in the advanced stages of
tumor progression. Hsp90 inhibition by ansamycins
has been reported to suppress cancer cell motility and
invasion through depletion of the HGF/c-Met signaling
pathway in both leiomyosarcoma and glioblastoma cell
lines [41]. Another novel finding of the present study
is the notable expression and constitutive activation of
c-Met receptor in T24 bladder cancer cells, whereas in
RT4 and RT112 cells total c-Met protein levels were
either absent (RT4) or barely detectable (RT112).
Finally, in this study, we have clearly demonstrated
that T24 cell line expresses high amounts of phos-
phorylated IGF-IR, Akt, FOXOs, p44/42 and c-Met
proteins and exhibits strong migration dynamics,
which could well be associated with a more invasive
and metastatic potency, exactly as a result of this over-
activated signaling network. Nevertheless, we have
shown that the inhibitory effect of 17-AAG on T24
cells is reflected on the significant decrease of both
total and phosphorylated c-Met protein levels, with
subsequent suppression of other oncogenic parameters,
such as increased cell proliferation and motility, hence
critically contributing to the impairment of aggressive
cancer cell phenotype [41-43].
Conclusions
We have clearly demonstrated the existence of a dose-
dependent and cell type-specific inhibitory effect of 17-
AAG on cell proliferation, survival and motility in
human urinary bladder cancer cells. These responses are
likely induced by the pronounced downregulation of
multiple Hsp90 protein clients, as well as their asso-
ciated and downstream components, such as Cyclin D1,
Cdk4, pRb, E2F1, IGF-IR, Akt, FOXOs, IKKs, NF-B,
cIAP1, Survivin, ERK1/2 and c-Met, resulting in cell
cycle arrest, decline in cell motility and potent activation
of Caspase-mediated apoptosis (Figure 11).
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Figure 11 Schematic representation of the effects of Hsp90
inhibition on multiple signaling pathways in human urinary
bladder cancer cells. Downregulated molecules examined herein
are shown in bold letters, while dashed arrows depict “cross-talk”
interactions (RTKs: Receptor Tyrosine Kinases, TFs: Transcription
Factors).
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